Selective Serotonin Reuptake Inhibitors for the Treatment of Depression

Analogue-Based Drug Discovery II

Volumn , Issue , 2010, Pages 269-295

  Childers Jr , Wayne E ^a   Rotella, David P ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT autoreceptors; Antidepressant activity; Norepinephrine transporter; Obsessive compulsive disorder; Rat synaptosomes; Selective serotonin reuptake inhibitors

Indexed keywords

EID: 84887228813     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630035.ch11     Document Type: Chapter

References (122)

1. Kasper, S., Höflich, G., Scholl, H.-P., and Möller, H.-J. (1994) Safety and antidepressant efficacy of selective serotonine reuptake inhibitors. Hum. Psychopharmacol., 9, 1-12.
2. Nemeroff, C.B., DeVane, C.L., and Pollock, B.G. (1996) Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry, 153, 311-320.
3. Thase, M., Feighner, J., and Lydiard, R. (2001) Citalopram treatment of fluoxetine nonresponders. J. Clin. Psychiatry, 62, 683-687.
4. For leading references, see Stahl, S.M. (2004) Selectivity of SSRIs: individualizing patient care through rational treatment choices. Int. J. Psychiatr. Clin. Pract., 8 (Suppl. 1), 3-10.
5. For references and a discussion, see Grimsley, S.R. and Jann, W. (1992) Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors. Clin. Pharmacy, 11, 930-957.
6. Preskorn, S.H. (1996) Basic neuropharmacology of SSRIs, in Clinical Pharmacology of SSRIs, Professional Communications, Inc., Caddo, OK, available at www.preskorn.com.
7. Koe, B.K., Weissman, A., Welch, W.M., and Browne, R.G. (1983) Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther., 226, 686-700.
8. Koe, B.K., Koch, S.W., Lebel, L.A., Minor, K.W., and Page, M.G. (1987) Sertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of betaadrenoceptor system of rat brain. Eur. J. Pharmacol., 141, 187-194.
9. Banerjee, S.P.,Kung, L.S., Riggi, S.J., and Chanda, S.K. (1977) Development of b-adrenergic receptor subsensitivity by antidepressants. Nature, 268, 455-456.
10. Christensen, A.V., Fjalland, B., Pedersen, V., Danneskiold-Samsøe, P., and Svendsen, O. (1997) Pharmacology of a new phthalane (Lu 10-171), with specific 5-HTuptake inhibiting properties. Eur. J. Pharmacol., 41, 153-162.
11. Hyttel, J. (1977) Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology, 51, 225-233.
12. Hyttel, J., Bøgesø, K.P., Perregard, J., and Sánchez, C. (1992) The pharmacological effect of citalopram resides in the (S)- (+)-enantiomer. J. Neural Transm., 88, 157-160.
13. Owens, M.J., Knight, D.L., and Nemeroff, C.B. (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry, 50, 345-350.
14. Mørk, A., Kreilgaard, M., and Sánchez, C. (2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology, 45, 167-173.
15. Chen, F., Breum-Larsen, M., Sánchez, C., and Wiborg, O. (2005) The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol., 15, 193-198.
16. Sánchez, C., Bøgesø, K.P., Ebert, B., Reines, E.H., and Braestrup, C. (2004) Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology, 174, 163-176.
17. Claassen, V., Davies, J.E., Hertting, G., and Placheta, P. (1977) Fluvoxamine, a specific 5-HT uptake inhibitor. Br. J. Pharmacol., 60, 505-516.
18. Claassen, V. (1983) Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br. J. Clin. Pharmacol., 15, 349S-355.
19. Hrdina, P.D. (1991) Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine. J. Psychiatr. Neurosci., 16, 10-18.
20. Sulser, F., Watts, J., and Brodif, B.B. (1962) On the mechanism of antidepressant action of imipramine-like drugs. Ann. N.Y. Acad. Sci., 96, 279-288.
21. Ross, S.B. and Renyi, A.L. (1967) Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents. Eur. J. Pharmacol., 2, 181-186.
22. Yoshiyaki, T. and Tonda, K. (1980) Effects of tricyclic antidepressants on tetrabenazine-induced depletion of brain monoamines in rats: I. Norepinephrine. Jpn. J. Pharmacol., 30, 721-729.
23. Palmer, K.J. and Benfield, P. (1994) Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in nondepressive disorders. CNS Drugs, 1, 57-87.
24. Wong, D.T., Horng, J.S., Bymaster, F.P., Hauser, K.L., and Molloy, B.B. (1974) A selective inhibitor of serotonin uptake: Lilly 110140, 3-(ptrifluoromethylphenoxy)- N-methyl-3-phenylpropylamine. Life Sci., 15, 471-479.
25. Wong, D.T., Bymaster, F.P., and Engleman, E.A. (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci., 57, 411-441.
26. Horng, J.S. andWong, D.T. (1976) Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets. Biochem. Pharmacol., 25, 865-867.
27. Lemberger, L., Rowe, H., Carmichael, R., Oldham, S., Horng, J.S., Bymaster, F.P., and Wond, D. (1978) Pharmacologic effects in man of a specific serotoninreuptake inhibitor. Science, 199, 436-437.
28. Wong, D.T. and Bymaster, F.P. (1983) Serotonin (5-HT) neuronal uptake binding sites in rat brain membranes labeled with [3H]-fluoxetine. Fed. Proc., 43, 1164-1172.
29. Fuller, R.W., Perry, K.W., and Molloy, B.B. (1975) Effect of 3-(ptrifluoromethylphenoxy)- N,N-methyl-3- phenylpropylamine on the depletion of brain serotonin by 4- chloroamphetamine. J. Pharmacol. Exp. Ther., 193, 793-803.
30. Wong, D.T., Bymaster, F.P., Reid, L.R., and Threlkeld, P.G. (1983) Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem. Pharmacol., 32, 1287-1293.
31. Wong, D.T., Threlkeld, P.G., and Robertson, D.W. (1991) Affinities of fluoxetine, its enantiomers and other inhibitors of serotonin uptake for subtypes of the serotonin receptor. Neuropsychoparmacology, 5, 43-47.
32. Wood, M.D., Glen, A., Gager, T.L., Blackburn, T.P., Lee, J.A., Sutiphong, J.A., Kumar, C., Carey, J.E., and Robinson, J.H. (1995) Comparison of 3H-mesulergine binding to the cloned rat, mouse and human 5-HT2C receptor and of 3H-ketanserin binding to the cloned human 5-HT2A receptor. Pharmacol. Commun., 5, 109-116.
33. Chen, Y.E., Peng, L., Zhang, X., Stolzenberg, J.-U., and Hertz, L. (1995) Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells. Brain Res. Bull., 38, 153-159.
34. Ni, Y.G. and Miledi, R. (1997) Blockage of 5-HT2C serotonin receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA, 94, 2036-2040.
35. Chanrion, B., laCour, C.M., Gavarini, S., Seimandi, M., Vincent, L., Pujol, J.-F., Bockaert, J., Marin, P., and Millan, M.J. (2008) Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5- hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol. Pharmacol., 73, 748-757.
36. Rosenzweig-Lipson, S., Dunlop, J., and Marquis, K. (2007) 5-HT2C receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect., 20, 565-571.
37. Wood, M.D., Thomas, D.R., andWatson, J.M. (2002) Therapeutic potential of serotonin antagonists in depressive disorders. Exp. Opin. Invest. Drugs, 11, 457-467.
38. Willner, P. (1996) Animal models of depression: validity and application. Adv. Biochem. Pharmacol., 49, 19-41.
39. Massol, J., Martin, P., and Puech, A.J. (1989) Antidepressant effects of tricyclic antidepressants and selective serotoninuptake blockers in diabetic rats. Diabetes, 38, 1161-1164.
40. Porsolt, R.D., Bertin, A., Blavet, N., Deniel, M., and Jalfre, M. (1979) Immobility induced by forced swimming in rats: effect of agents which modify central catacholamine and serotonin activity. Eur. J. Pharmacol., 57, 201-210.
41. Joly, D. and Sanger, D.J. (1986) The effects of fluoxetine and zimelidine on the behavior of olfactory bulbectomized rats. Pharmacol. Biochem. Behav., 24, 199-204.
42. Johnson, A.M. (1992) Paroxetine: a pharmacological review. Int. Clin. Psychopharmacol., 6 (Suppl.4), 15-24.
43. Dechant, K.L. and Clissold, S.P. (1991) Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illnesses. Drugs, 42, 225-253.
44. Gunasekara, N.S., Novel, S., and Benfield, P. (1998) Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs, 55, 85-120.
45. Buss Lassen, J. (1978) Potent and longlasting potentiation of two 5- hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors. Eur. J. Pharmacol., 47, 351-358.
46. Buss Larsen, J., McConnel, E.F.,McCabe, R.T., Dawson, T.M., and Grosser, B.I. (1978) Influence of the new 5HT-uptake inhibitor paroxetine on hypermotility in rats produced by p-chloroamphetamine (PCA) and 4,4-dimethyl-m-tyramine (H77/77). Psychopharmacology, 57, 151-153.
47. Thomas, D.R., Nelson, D.R., and Johnson, A.M. (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.
48. Habert, E., Graham, D., Tahraoui, L., Claustre, Y., and Langer, S.Z. (1985) Characterization of [3H]paroxetine binding to rat cortical membranes. Eur. J. Pharmacol., 118, 107-114.
49. Jenner, P.N. (1992) Paroxetine: an overview of dosage, tolerability and safety. Int. Clin. Psychopharmacol., 6 (Suppl. 4), 69-80.
50. Perna, G., Bertani, A., Caldirola, D., Smeraldi, E., and Bellodi, L. (2001) A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind clinical study. Pharmacopsychiatry, 34, 85-90.
51. Magnussen, I., Tonder, K., and Engbaek, F. (1982) Paroxetine, a potent selective long-acting inhibitor of synaptosomal 5- HTuptake in mice. J. Neural Transm., 55, 217-226.
52. Hassan, S.M.,Wainscott, G., and Turner, P. (1985) A comparison of the effect of paroxetine and amitriptylene on the tyramine pressor response test. Br. J. Clin. Pharmacol., 19, 705-706.
53. Zazpe, A., Artaiz, I., Labeaga, L., Lucero, M.L., and Orjales, A. (2007) Reversal of learned helplessness be selective serotonin reuptake inhibitors in rats is not dependent on 5-HT availability. Neuropharmacology, 52, 975-984.
54. Redmond, A.M., Kelly, J.P., and Leonard, B.E. (1994) Effect of paroxetine and fluvoxamine on behavioral changes in a number of paradigms in the olfactory bulbectomized rat model of depression. J. Serotonin Res., 1, 199-205.
55. Weiner, I., Schiller, D., Gaisler-Solomon, I., Green, A., and Joel, D. (2003) A comparison of drugs effects in latent inhibition and the forced-swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine and the antidepressants imipramine and paroxetine. Behav. Pharmacol., 14, 215-222.
56. Conner, T.J., Kelliher, P., Shen, Y., Harkin, A., Kelly, J.P., and Leonard, B.E. (2000) Effect of subchronic antidepressant treatments on behavioral, neurochemical and endocrine changes in the forced-swim test. Pharmacol. Biochem. Behav., 65, 591-597.
57. Varty, G.B., Cohen-Williams, M.E., and Hunter, J.C. (2003) The antidepressantlike effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav. Pharmacol., 14, 87-95.
58. Ripoll, N., Dennis, D.J.P., Dailly, E., Hascoet, M., and Bourin, M. (2003) Antidepressants-like effects in various mice strains in the tail suspension test. Behav. Brain Res., 143, 193-200.
59. Koe, B.K. (1975) Antidepressants (eds S. Fielding and H. Lal), pp. 143-180. Futura Publishing Company.
60. Carlsson, A., Corrodi, H., Fuxe, K., and Hokfelt, T. (1969) Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-a-ethyl-meta-tyramine. Eur. J. Pharmacol., 5, 357-366.
61. Coyle, J.T. and Snyder, S.H. (1969) Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science, 166, 899-901.
62. Koe, B.K. (1976) Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp. Ther., 175, 649-661.
63. Welch, W.M., Kraska, A.R., Sarges, R., and Koe, B.K. (1984) Nontricyclic antidepressant agents derived from cisand trans-1-amino-4-aryltetralins. J. Med. Chem., 27, 1508-1515.
64. See Sarges, R., Koe, B.K., Weissman, A., and Schaefer, J.P. (1974) Blockade of heart 3H-norepinephrine uptake by 4-phenyl-1-aminotetralines: implications for the active conformation of imipramine-like drugs. J. Pharmacol. Exp. Ther., 191, 393-402, for earlier work with this series of aminotetralins.
65. Bigler, A.J., Bøgesø, K.P., Toft, A., and Hansen, V. (1977) Quantitative structure-activity relationships in a series of selective 5-HTuptake inhibitors. Eur. J. Med. Chem., 12, 289-295.
66. Jørgensen, A.M., Tagmose, L., Jørgensen, A.M.M., Topiol, S., Sabio, M., Gundertofte, K., Bøgesø, K.P., and Peters, G.H. (2007) Homology modeling of the serotonin transporter: insights into the primary escitalopram binding site. ChemMedChem, 2, 815-826.
67. Henry, L.K., Field, J.R., Adkins, E.M., Parnas, M.L., Vaughan, R.A., Zou, M.-F., and Newman, A.H. (2006) Blakelely, Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem., 281, 2012-2023.
68. Andersen, J., Taboureau, O., Hansen, K.B., Olsen, L., Egebjerg, J., Strømgaard, K., and Kristensen, A.S. (2009) Location of the antidepressant binding site in the serotonin transporter. J. Biol. Chem., 284, 10276-10284.
69. Jacqout, C., David, D.J., Gardier, A.M., and Sánchez, C. (2007) Escitalopram and citalopram: the unexpected role of the R-enantiomer. L'Encephale, 33, 179-187.
70. Boschman, T.A.C. and deWinter, M.L. (1980) In vitro inhibition of ADP-induced platelet aggregation by O-(aminoalkyl) oxime ethers. Eur. J. Med. Chem., 15, 351-356.
71. van Dijk, J. and Davies, J.E. (1972) US Patent 3,692,835, September 19.
72. Giurgea, M., Dauby, J., Levis, S., and Giurgea, C. (1963) A modified antitetrabenazine test for screening antidepressive drugs. Med. Exp. Int. J. Exp. Med., 9, 249-262.
73. Sulser, F., Watts, J., and Brodif, B.B. (1962) On the mechanism of antidepressant action of imipramine-like drugs. Ann. N.Y. Acad. Sci., 96, 279-288.
74. Ross, S.B. and Renyi, A.L. (1967) Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents. Eur. J. Pharmacol., 2, 181-186.
75. Yoshiyaki, T. and Tonda, K. (1980) Effects of tricyclic antidepressants on tetrabenazine-induced depletion of brain monoamines in rats. Jpn. J. Pharmacol., 30, 721-729.
76. Claassen, V., Davies, J.E., Hertting, G., and Placheta, P. (1977) Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br. J. Pharmacol., 60, 505-516.
77. Welle, H.B.A. and Claassen, V. (1977) US Patent 4,060,631, November 29.
78. Welle, H.B.A. and Claassen, V. (1978) US Patent 4,085,225, April 18.
79. Welle, H.B.A. and Claassen, V. (1978) US Patent 4,081,551, March 28.
80. Welle, H.B.A. and Claassen, V. (1980) US Patent 4,192,893, March 11.
81. Bozdag, O., Gumusel, B., Demirdamar, R., Buyukbingol, E., Rolland, Y., and Ertan, R. (1998) Synthesis of some novel oxime ether derivatives and their activity in the ?behavioral despair test?. Eur. J. Med. Chem., 33, 133-141.
82. Wong, D.T., Bymaster, F.P., and Engleman, E.A. (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci., 57, 411-441.
83. Grunewald, G.L. andCreese,M.W. (1986) Conformational analysis of nisoxetine and fluoxetine, selective inhibitors of norepinephrine and serotonin reuptake: are conformational differences an explanation of neurotransmitter selectivity? Drug Des. Delivery, 1, 23-37.
84. Wong, D.T., Mymaster, F.P., Horng, J.S., and Molloy, B.B. (1975) A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(ptrifluoromethylphenoxy)- N-methyl-3- phenylpropyl amine. J. Pharmacol. Exp. Ther., 193, 804-811.
85. Orjales, A., Mosquera, R., Toledo, A., Pumar, M.C., Garcia, N., Cortizo, L., Labeaga, L., and Innerarity, A. (2003) Syntheses and binding studies of new [(aryl)]aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters. J. Med. Chem., 46, 5512-5532.
86. Stocking, E.M., Miller, J.M., Barbier, A.J., Wilson, S.J., Boggs, J.D., McAllister, H.M., Wu, J., Lovenberg, T.W., Carruthers, N.I., and Wolin, R.L. (2007) Synthesis and biological evaluation of diamine-based histamine H3 antagonists with serotonin reuptake inhibitor activity. Bioorg. Med. Chem. Lett., 17, 3130-3135.
87. Williams, D.A. (2007) Antidepressants, in Foye?s Principles ofMedicinal Chemistry, 6th edn (eds T.L. Lemke and D.A. Williams), Lippincott Williams & Wilkins, Baltimore, MD, pp. 547-600.
88. Olivier, B., Soudijn, S., and van Wijngaarden, I. (2000) Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog. Drug Res., 54, 61-119.
89. Christensen, J.A. and Squires, R.F. (1977) US Patent 4,007,196.
90. Plenge, P., Mellerup, E.T., Honere, T., and le Fever Honore, P. (1987) J. Pharm. Pharmacol., 39, 877-882.
91. Owen, M.J., Morgan,W.N., Plott, S.J., and Nemeroff, C.B. (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther., 283, 1305-1322.
92. Mathis, C.A., Gerdes, J.M., Enas, J.D., Whitney, J.M., Taylor, S.E., Zhang, Y., McKenna, D.J., Havlik, S., and Peroutka, S.J. (1992) J. Pharm. Pharmacol., 44, 801-805.
93. For a computational analysis, see Chang, A.S., Chang, S.M., and Starnes, D.M. (1993) Structure-activity relationships of serotonin transport: relevance to nontricyclic antidepressant interactions. Eur. J. Pharmacol., 247, 239-248.
94. Keverline-Frantz, K.I., Boja, J.W., Kuhar, M.J., Abraham, P., Burgess, J.P., Lewin, A.H., and Carroll, F.I. (1998) Synthesis and ligand binding of tropane ring analogs of paroxetine. J. Med. Chem., 41, 247-257.
95. Thomas, D.R., Nelson, D.R., and Johnson, A.M. (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200.
96. Finley, P.R. (1994) Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother., 28, 1359-1369.
97. Kasper, S.,Höflich, G., Scholl, H.-P., and Möller, H.-J. (1994) Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Hum. Psychopharmacol., 9, 1-12.
98. de Jonghe, F. and Swinkels, J. (1997) Selective serotonin reuptake inhibitorsrelevance of differences in their pharmacological and clinical profiles. CNS Drugs, 7, 451-467.
99. Moore, N., Verdoux, H., and Fantino, B. (2005) Prospective, multicenter, randomized double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol., 20, 131-137.
100. Kasper, S., Sacher, J., Klein, N., Mossaheb, N., Attarbaschi-Steiner, T., Lanzenberger, R., Spindelegger, C., Asenbaum, S., Holik, A., and Dudczak, R. (2009) Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int. Clin. Psychopharmacol., 24, 119-125.
101. Schmidt, K., Nolte-Zenker, B., Patzer, J., Bauer, M., Schmidt, L.G., and Heinz, A. (2001) Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence. Pharmacopsychiatry, 34, 66-72.
102. Tulloch, I.F., Lowther, S., Crompton, M., De Paermentier, F., and Horton, R.W. (1995) Pharmacological differences between selective serotonin reuptake inhibitors: interaction with 5-HT and sigma binding sites in human brain in vitro. Eur. Neuropsychopharmacol., 5 (Suppl. 3), 281.
103. Bolden-Watson, C. and Richelson, E. (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life. Sci., 52, 1023-1029.
104. Zimmerman, M., McDermut, W., and Mattia, J.I. (2000) Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am. J. Psychiatry, 157, 1337-1340.
105. Narita, H., Hashimoto, K., Tomitaka, S., and Minabe, Y. (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of s receptors in rat brain. Eur. J. Pharmacol., 307, 117-119.
106. Montejo-Gonzaléz, A.L., Liorca, G., Izquierdo, J.A., Ledesma, A., Bousoño, M., Calcedo, A., Carrasco, J.L., Ciudad, J., Daniel, E., De la Gandara, J., Derecho, J., Franco, M., Gomez, M.J., Macias, J.A., Martin, T., Perez, V., Sanchez, J.M., Sanchez, S., and Vicens, E. (1997) SSRIinduced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex. Marital Ther., 22, 85-96.
107. Angulo, J., Peiró, C., Sanchez-Ferrer, C.F., Gabancho, S., Cuevas, P., Gupta, S., and Sáenz de Tejada, I. (2001) Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br. J. Pharmacol., 134, 1190-1194.
108. For a summary and leading references, see Caccia, S. (2004) Metabolism of the newest antidepressants: comparisons with related predecessors. IDrugs, 7, 143-150.
109. von Moltke, L.L., Greenblatt, D.K., Giancarlo, G.M., Granda, B.W., and Harmatz, J.S. (2001) Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug. Metab. Dispos., 29, 1102-1109.
110. Brosen, K. and Naranjo, C.A. (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur. Neuropsychopharmacol., 11, 275-283.
111. Hiemke, C. and Härtter, S. (2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther., 85, 11-28.
112. Brøsen, K., Skjelbo, E., Rasmussen, B.B., Pousen, H.E., and Loft, S. (1993) Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol., 45, 1211-1214.
113. Harvey, A.T. and Preskorn, S.H. (1995) Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch. Gen. Pyschiatry, 52, 783-784.
114. Lane, R.M. (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol., 11 (Suppl. 5), 31-61.
115. Pigott, T.A., Pato, M.T., Bernstein, S.E., Grover, G.N., Hill, J.L., Tolliver, T.J., and Murphy, D.L. (1990) Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessivecompulsive disorder. Behavioral and biological results. Arch. Gen. Psychiatry, 47, 926-932.
116. Chouinard, G., Goodman, W., Greist, J., Jenike, M., Rasmussen, S., White, K., Hackett, E., Gaffney, M., and Bick, P.A. (1990) Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol. Bull., 26, 279-284.
117. Ballenger, J.C., Wheadon, D.E., Steiner, N., Bushnell, W., and Gergel, I.P. (1998) Double-blind, fixed-dose, placebocontrolled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatry, 155, 36-42.
118. Schuurmans, J., Comijs, H., Emmelkamp, P.M., Gundy, C.M., Weijnen, I., van den Hout, M., and van Dyck, R. (2006) A randomized, controlled trial of the effectiveness of cognitivebehavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am. J. Geriatr. Psychiatry, 14, 255-263.
119. Leombruni, P., Amianto, F., Delsedime, N., Gramaglia, C., Abbate-Daga, G., and Fassino, S. (2006) Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv. Ther., 23, 481-494.
120. For a summary of recent results, see Silver, H. (2004) Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Exp. Opin. Pharmacother., 5, 2053-2058.
121. Kim, K.Y. and Wood, B.E. (2005) Trends in Serotonin Uptake Inhibitor Research (ed. A.C. Shirley), Nova Biomedical, pp. 145-156.
122. Tatsumi, M., Groshan, K., Blakely, R.D., and Richelson, E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol., 340, 249-258.